Li H, Yang L, Guo Z, Tang Y, Chen N, Lu Y, Ni J. Successful treatment of refractory cancer pain with morphine and ropivacaine: A case report.
Medicine (Baltimore) 2017;
96:e7052. [PMID:
28562567 PMCID:
PMC5459732 DOI:
10.1097/md.0000000000007052]
[Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
RATIONALE
Pain is one of the most common and distressing symptoms experienced by cancer patients. Cancer pain is a complex phenomenon with physical, psychological, social, and cognitive domains. Although opioids remain a cornerstone of cancer pain management, they are not effective in all patients. This case highlights the successful treatment of an opioid-refractory severe cancer pain crisis with ropivacaine infusion and subsequent rapid tapering of opioid dose.
PATIENT CONCERNS
This report illustrates the use of ropivacaine for cancer pain. A 62-year-old man with metastatic lung cancer was admitted to the hospital with uncontrolled chest-back and abdominal pain.
DIAGNOSES
The patient was diagnosed as refractory cancer pain.
INTERVENTIONS
Successful treatment with morphine and ropivacaine was performed to obtain longer opioid refractory severe cancer pain.
OUTCOMES
At 1, 3, and 6 months postoperative review, 70-75% relief of pain was achieved with overall activity was improved. The analgesic effect was stable during the 6-month follow-up period. No complications were reported during the follow-up period.
LESSONS
Our report demonstrates that ropivacaine is successful treatment for cancer pain in this case. It will supply us a novel navigation in cancer pain treatments. Meanwhile, this finding still needs additional study for confirmation.
Collapse